FDA approves Lundbeck’s VYEPTI™ (eptinezumab-jjmr) – the first and only intravenous preventive treatment for migraine

Lundbeck today announced that VYEPTI™ (eptinezumab-jjmr) has been approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine in adults and will be available in April 2020. The recommended dose is 100 mg every 3 months; some patients may benefit from a dose of 300 mg. VYEPTI is the first FDA-approved intravenous (IV) treatment for migraine prevention.

The Ultimate Guide to Finding the Best Neurologist in Singapore: Beyond Stroke and Parkinson’s — Managing Headaches, Pain and More

Why Neurology Matters More Than You Think When people hear […]

Stroke: Controlling Risk Factors

Source from: https://www.healthhub.sg/a-z/medical-and-care-facilities/stroke-controllable-risks

Dr Charles Siow

MB BCh BAO ｜ LRCPI ｜ LRCSI

Tailored Care for Headaches, Pain and Neurological Health

This article has been medically reviewed by Dr Charles Siow

Dr Charles Siow has over 20 years of experience as a neurologist, with the past 18 years dedicated to his practice in Singapore. He is committed to improving the lives of his patients by providing comprehensive care across a wide range of neurological disorders.